Skip to main content
NASDAQ:IMAB

I-Mab Competitors

$62.07
+3.31 (+5.63 %)
(As of 05/12/2021 04:30 PM ET)
Add
Compare
Today's Range
$58.71
$62.13
50-Day Range
$44.38
$64.43
52-Week Range
$17.86
$65.94
Volume650,921 shs
Average Volume367,591 shs
Market Capitalization$4.49 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

I-Mab (NASDAQ:IMAB) Vs. ALNY, ELAN, BMRN, ZLAB, GRFS, and RDY

Should you be buying IMAB stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to I-Mab, including Alnylam Pharmaceuticals (ALNY), Elanco Animal Health (ELAN), BioMarin Pharmaceutical (BMRN), Zai Lab (ZLAB), Grifols (GRFS), and Dr. Reddy's Laboratories (RDY).

Alnylam Pharmaceuticals (NASDAQ:ALNY) and I-Mab (NASDAQ:IMAB) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Valuation and Earnings

This table compares Alnylam Pharmaceuticals and I-Mab's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alnylam Pharmaceuticals$219.75 million71.33$-886,120,000.00($8.11)-16.44
I-Mab$4.31 million1,042.73$-208,560,000.00($28.90)-2.15

I-Mab has lower revenue, but higher earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than I-Mab, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Alnylam Pharmaceuticals and I-Mab's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alnylam Pharmaceuticals-222.19%-65.96%-31.38%
I-MabN/AN/AN/A

Analyst Ratings

This is a summary of recent recommendations and price targets for Alnylam Pharmaceuticals and I-Mab, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alnylam Pharmaceuticals08802.50
I-Mab00403.00

Alnylam Pharmaceuticals presently has a consensus price target of $168.7333, indicating a potential upside of 26.52%. I-Mab has a consensus price target of $70.00, indicating a potential upside of 12.78%. Given Alnylam Pharmaceuticals' higher possible upside, equities analysts clearly believe Alnylam Pharmaceuticals is more favorable than I-Mab.

Insider & Institutional Ownership

92.4% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 16.6% of I-Mab shares are held by institutional investors. 3.5% of Alnylam Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

I-Mab beats Alnylam Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Elanco Animal Health (NYSE:ELAN) and I-Mab (NASDAQ:IMAB) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Valuation and Earnings

This table compares Elanco Animal Health and I-Mab's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Elanco Animal Health$3.07 billion4.94$67.90 million$1.0630.28
I-Mab$4.31 million1,042.73$-208,560,000.00($28.90)-2.15

Elanco Animal Health has higher revenue and earnings than I-Mab. I-Mab is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Elanco Animal Health and I-Mab's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Elanco Animal Health-8.45%3.43%2.04%
I-MabN/AN/AN/A

Analyst Ratings

This is a summary of recent recommendations and price targets for Elanco Animal Health and I-Mab, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Elanco Animal Health13902.62
I-Mab00403.00

Elanco Animal Health presently has a consensus price target of $32.2273, indicating a potential upside of 0.40%. I-Mab has a consensus price target of $70.00, indicating a potential upside of 12.78%. Given I-Mab's stronger consensus rating and higher possible upside, analysts clearly believe I-Mab is more favorable than Elanco Animal Health.

Insider & Institutional Ownership

86.8% of Elanco Animal Health shares are held by institutional investors. Comparatively, 16.6% of I-Mab shares are held by institutional investors. 0.1% of Elanco Animal Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Elanco Animal Health beats I-Mab on 8 of the 13 factors compared between the two stocks.

BioMarin Pharmaceutical (NASDAQ:BMRN) and I-Mab (NASDAQ:IMAB) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Valuation and Earnings

This table compares BioMarin Pharmaceutical and I-Mab's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioMarin Pharmaceutical$1.70 billion8.11$-23,850,000.00$0.071,080.00
I-Mab$4.31 million1,042.73$-208,560,000.00($28.90)-2.15

BioMarin Pharmaceutical has higher revenue and earnings than I-Mab. I-Mab is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BioMarin Pharmaceutical and I-Mab's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioMarin Pharmaceutical45.74%4.34%2.84%
I-MabN/AN/AN/A

Analyst Ratings

This is a summary of recent recommendations and price targets for BioMarin Pharmaceutical and I-Mab, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioMarin Pharmaceutical071002.59
I-Mab00403.00

BioMarin Pharmaceutical presently has a consensus price target of $118.20, indicating a potential upside of 56.35%. I-Mab has a consensus price target of $70.00, indicating a potential upside of 12.78%. Given BioMarin Pharmaceutical's higher possible upside, equities analysts clearly believe BioMarin Pharmaceutical is more favorable than I-Mab.

Insider & Institutional Ownership

97.7% of BioMarin Pharmaceutical shares are held by institutional investors. Comparatively, 16.6% of I-Mab shares are held by institutional investors. 2.2% of BioMarin Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

BioMarin Pharmaceutical beats I-Mab on 11 of the 13 factors compared between the two stocks.

Zai Lab (NASDAQ:ZLAB) and I-Mab (NASDAQ:IMAB) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Profitability

This table compares Zai Lab and I-Mab's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zai LabN/AN/AN/A
I-MabN/AN/AN/A

Insider & Institutional Ownership

81.3% of Zai Lab shares are held by institutional investors. Comparatively, 16.6% of I-Mab shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations and price targets for Zai Lab and I-Mab, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zai Lab00503.00
I-Mab00403.00

Zai Lab presently has a consensus price target of $197.8460, indicating a potential upside of 35.92%. I-Mab has a consensus price target of $70.00, indicating a potential upside of 12.78%. Given Zai Lab's higher possible upside, equities analysts clearly believe Zai Lab is more favorable than I-Mab.

Valuation and Earnings

This table compares Zai Lab and I-Mab's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zai Lab$12.98 million1,061.81$-195,070,000.00($3.03)-48.04
I-Mab$4.31 million1,042.73$-208,560,000.00($28.90)-2.15

Zai Lab has higher revenue and earnings than I-Mab. Zai Lab is trading at a lower price-to-earnings ratio than I-Mab, indicating that it is currently the more affordable of the two stocks.

Summary

Zai Lab beats I-Mab on 7 of the 8 factors compared between the two stocks.

I-Mab (NASDAQ:IMAB) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, dividends, analyst recommendations, institutional ownership, valuation and profitability.

Profitability

This table compares I-Mab and Grifols' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
I-MabN/AN/AN/A
Grifols12.79%10.65%4.79%

Insider & Institutional Ownership

16.6% of I-Mab shares are owned by institutional investors. Comparatively, 15.2% of Grifols shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and price targets for I-Mab and Grifols, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
I-Mab00403.00
Grifols03502.63

I-Mab currently has a consensus target price of $70.00, indicating a potential upside of 12.78%. Given I-Mab's stronger consensus rating and higher possible upside, research analysts clearly believe I-Mab is more favorable than Grifols.

Valuation & Earnings

This table compares I-Mab and Grifols' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
I-Mab$4.31 million1,042.73$-208,560,000.00($28.90)-2.15
Grifols$5.71 billion2.18$700.16 million$1.1715.49

Grifols has higher revenue and earnings than I-Mab. I-Mab is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Summary

Grifols beats I-Mab on 8 of the 12 factors compared between the two stocks.

I-Mab (NASDAQ:IMAB) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, dividends, analyst recommendations, institutional ownership, valuation and profitability.

Profitability

This table compares I-Mab and Dr. Reddy's Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
I-MabN/AN/AN/A
Dr. Reddy's Laboratories8.23%16.33%10.79%

Insider & Institutional Ownership

16.6% of I-Mab shares are owned by institutional investors. Comparatively, 12.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and price targets for I-Mab and Dr. Reddy's Laboratories, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
I-Mab00403.00
Dr. Reddy's Laboratories00303.00

I-Mab currently has a consensus target price of $70.00, indicating a potential upside of 12.78%. Dr. Reddy's Laboratories has a consensus target price of $70.00, indicating a potential downside of 2.06%. Given I-Mab's higher possible upside, research analysts clearly believe I-Mab is more favorable than Dr. Reddy's Laboratories.

Valuation & Earnings

This table compares I-Mab and Dr. Reddy's Laboratories' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
I-Mab$4.31 million1,042.73$-208,560,000.00($28.90)-2.15
Dr. Reddy's Laboratories$2.32 billion5.13$259 million$2.7925.62

Dr. Reddy's Laboratories has higher revenue and earnings than I-Mab. I-Mab is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Summary

Dr. Reddy's Laboratories beats I-Mab on 8 of the 12 factors compared between the two stocks.


I-Mab Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
2.0$133.36+0.7%$15.68 billion$219.75 million-17.03
Elanco Animal Health logo
ELAN
Elanco Animal Health
1.8$32.10+0.7%$15.28 billion$3.07 billion-56.32Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.1$75.60+0.1%$13.82 billion$1.70 billion17.30Insider Selling
Zai Lab logo
ZLAB
Zai Lab
1.6$145.56+3.1%$13.78 billion$12.98 million-48.04Earnings Announcement
Gap Down
Grifols logo
GRFS
Grifols
1.3$18.12+3.0%$12.83 billion$5.71 billion16.18
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.3$71.47+0.4%$11.93 billion$2.32 billion59.07Upcoming Earnings
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.6$10.27+0.2%$11.19 billion$16.89 billion-2.79Analyst Report
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
1.9$175.90+1.2%$9.89 billion$2.16 billion55.49Analyst Report
Bausch Health Companies logo
BHC
Bausch Health Companies
1.9$27.92+1.8%$9.83 billion$8.60 billion-5.12
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.6$36.18+2.3%$9.11 billionN/A0.00Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Down
United Therapeutics logo
UTHR
United Therapeutics
1.7$195.49+0.6%$8.70 billion$1.45 billion18.49Earnings Announcement
Analyst Report
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$153.18+1.7%$7.88 billion$3.34 million-19.89Earnings Announcement
Analyst Upgrade
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$49.48+0.7%$7.33 billion$40.56 million-14.51Earnings Announcement
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$68.70+1.6%$7.27 billion$87.99 million-81.79Analyst Revision
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$136.96+2.4%$7.18 billion$14.98 million-16.68Upcoming Earnings
News Coverage
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.7$106.40+2.0%$7.18 billion$103.71 million-24.24Analyst Report
Analyst Revision
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.3$218.96+0.0%$6.86 billion$311.33 million-127.30
Perrigo logo
PRGO
Perrigo
2.2$45.76+3.1%$5.92 billion$4.84 billion-762.54Earnings Announcement
Unusual Options Activity
News Coverage
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$73.89+3.9%$5.67 billion$380.83 million-9.45Earnings Announcement
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$91.65+2.3%$5.47 billion$66.51 million16.91
Allakos logo
ALLK
Allakos
1.7$98.89+0.2%$5.30 billionN/A-36.09Earnings Announcement
News Coverage
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$37.31+1.7%$5.26 billion$1.12 billion77.73Earnings Announcement
Analyst Report
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$36.33+3.3%$5.14 billion$150,000.00-17.14Earnings Announcement
Unusual Options Activity
Galapagos logo
GLPG
Galapagos
1.3$74.14+0.7%$4.82 billion$1.00 billion-11.23Analyst Report
Gap Down
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$68.27+3.2%$4.37 billionN/A-5.56Earnings Announcement
Analyst Report
Unusual Options Activity
News Coverage
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$73.88+0.4%$4.34 billion$6.87 million-7.14Analyst Revision
Schrödinger logo
SDGR
Schrödinger
1.6$59.68+3.5%$4.32 billion$85.54 million0.00Analyst Report
News Coverage
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.5$54.32+3.4%$3.93 billion$117.91 million-11.02
LEGN
Legend Biotech
1.3$30.35+2.7%$3.93 billion$64.39 million0.00
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$61.23+2.4%$3.80 billion$806.43 million-8.67Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$23.70+7.7%$3.80 billion$204.89 million-29.63
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$46.59+0.1%$3.75 billionN/A-6.28
Alkermes logo
ALKS
Alkermes
1.2$22.44+0.4%$3.60 billion$1.17 billion-48.78
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$115.68+0.4%$3.39 billionN/A-57.55Earnings Announcement
Analyst Revision
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.57+3.9%$3.39 billion$114.62 million-7.49Earnings Announcement
Analyst Report
Analyst Revision
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.83+4.5%$3.34 billion$339.08 million-12.69Analyst Report
Analyst Revision
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$65.94+1.5%$3.24 billionN/A-18.79Earnings Announcement
Analyst Upgrade
Analyst Revision
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.2$58.60+0.3%$3.15 billion$1.11 billion18.84Analyst Report
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$37.54+1.1%$3.05 billion$60,000.00-11.66Earnings Announcement
Analyst Revision
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$81.62+1.8%$3.01 billion$26.52 million-7.19Earnings Announcement
Arvinas logo
ARVN
Arvinas
1.7$63.01+2.7%$3.00 billion$42.98 million-24.61
Insmed logo
INSM
Insmed
1.2$26.46+1.9%$2.79 billion$136.47 million-10.18Earnings Announcement
Analyst Report
Unusual Options Activity
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.14+0.1%$2.76 billion$644.77 million-10.29Upcoming Earnings
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$38.29+1.2%$2.73 billion$306.98 million-5.48
MorphoSys logo
MOR
MorphoSys
0.3$19.95+2.0%$2.68 billion$80.43 million95.00News Coverage
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.3$61.98+2.0%$2.67 billion$421.03 million21.82Analyst Report
News Coverage
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$41.61+1.1%$2.57 billionN/A-22.86Earnings Announcement
Gap Up
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.4$58.91+2.1%$2.49 billionN/A0.00
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.22+4.1%$2.45 billion$182.24 million-8.02Earnings Announcement
ALX Oncology logo
ALXO
ALX Oncology
1.9$54.68+10.8%$2.44 billionN/A0.00
This page was last updated on 5/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.